Literature DB >> 19086840

EUTOS for chronic myeloid leukemia shows improved management and dose optimization is required.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19086840     DOI： 10.2217/14796694.4.6.755

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  2 in total

Review 1.  Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?

Authors:  Margaret von Mehren; Nicolas Widmer
Journal:  Cancer Treat Rev       Date:  2010-11-24       Impact factor: 12.111

2.  Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy.

Authors:  Leiming Xia; Wei Qian; Mingzhen Yang; Qingsheng Li; Fei Liu; Yanyan Xie
Journal:  Onco Targets Ther       Date:  2015-09-07       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.